Features | Partner Sites | Information | LinkXpress
Sign In
ElsMed
Ampronix
Schiller

Early PET-Negative Stage I/II Hodgkin Lymphoma Patients Show Increased Risk of Early Relapse when Radiotherapy Is Not Used

By Medimaging International staff writers
Posted on 23 Apr 2014
Image: Micrograph of Hodgkin lymphoma. Lymph node fine-needle aspiration (FNA) specimen. Field stain (Photo courtesy of Wikimedia Commons).
Image: Micrograph of Hodgkin lymphoma. Lymph node fine-needle aspiration (FNA) specimen. Field stain (Photo courtesy of Wikimedia Commons).
Analysis of a new study indicates an increased risk of early relapse when excluding radiotherapy in early positron emission tomography (PET) scan-negative patients with stage I/II Hodgkin’s lymphoma.

The interim analysis of the intergroup EORTC-LYSA-FIL 20051 H10 trial was published online March 17, 2014, in the Journal of Clinical Oncology. Early outcome, however, was excellent in both arms, and the final analysis should reveal whether these preliminary findings are upheld over time.

Dr. J.M.M. Raemaekers, from the Radboud University Medical Center (Nijmegen, The Netherlands), and central coordinator of the study stated, “The standard treatment for patients with clinical stage I/II Hodgkin’s lymphoma is ABVD [adriamycin, bleomycin, vinblastin and dacarbazin] chemotherapy followed by radiotherapy. Striking the right balance between initial cure through combined modality treatment and accepting a higher risk of late complications, and a higher recurrence rate after omitting radiotherapy in subsets of patients who will subsequently need intensive salvage treatment, is a matter of unsettled debate.”

The main objective of the H10 trial was to evaluate whether involved-node radiotherapy could be omitted without loss of efficacy in terms of progression-free survival in patients with stage I/II Hodgkin’s lymphoma who had a negative early PET scan after two cycles of ABVD chemotherapy. This interim trial analysis included a total of 1,137 patients with untreated clinical stage I/II Hodgkin’s lymphoma. Of these, 444 patients had favorable and 693 unfavorable prognoses. Patients in each prognostic group were randomized between standard and experimental treatment and first received two cycles of ABVD chemotherapy. Patients in the experimental arm who attained a negative early PET scan after the two cycles of ABVD chemotherapy were spared involved-node radiotherapy.

One progression occurred in the standard arm and nine progressions occurred in the research arm, for patients with a favorable prognosis and a negative early PET scan. For patients with unfavorable prognosis and a negative early PET scan, seven events occurred in the standard arm and 16 events occurred in the research arm. Even though there were few events and the median follow-up time short, the Independent Data Monitoring Committee concluded it was unlikely that the final results would show noninferiority for the experimental treatment. They, therefore, advised that randomization should be stopped for early PET-negative patients.
The study was closed for recruitment in June 2011 with a total of 1952 patients. The intergroup EORTC 20051 H10 trial is coordinated by the EORTC Lymphoma Group in collaboration with the LYmphoma Study Association (LYSA) and the Fondazione Italiana Linfomi (FIL). It is being conducted in 159 sites in eight countries: Belgium, Croatia, Denmark, France, Italy, Slovakia, Switzerland, and The Netherlands.

Related Links:

Radboud University Medical Center



Channels

Radiography

view channel
Image: SkyFlow scatter correction algorithm (Photo courtesy of Philips Healthcare).

Scatter Correction Algorithm Enhances Digital Radiography DR Exams with a Grid

A new scatter correction algorithm can provide high chest image contrast without grid handling. When doing digital radiography (DR) exams without a grid, Philips Healthcare’s (Best, The Netherlands)... Read more

MRI

view channel

Dyslexic Patients Shown to Have Disordered Network Connections in the Brain

Scientists conducted a whole-brain functional connectivity analysis of dyslexia using functional magnetic resonance imaging (fMRI), and revealed how brain activity is disordered in dyslexic patients. Dyslexia is a neurologic reading disability that occurs when the regions of the brain that process written language do... Read more

General/Advanced Imaging

view channel
Image: From left, Guy Genin, PhD, John Boyle and Stavros Thomopoulos, PhD, watch as a sample is exposed to stress and force. They have developed algorithms that may lead to the ability to identify weak spots in tendons, muscles and bones (Photo courtesy of Washington University in St. Louis).

Image Analysis Algorithms Devised to Find Weak Spots in Muscles, Tendons, and Bones prone to Tearing, Breaking

Researchers have developed algorithms to detect weak spots in muscles, tendons, and bones predisposed to tearing or breaking. The technology, which needs to be further refined before it is used in patients,... Read more

Imaging IT

view channel

Interactive Dashboard and Visualization Tool Designed for Oncologists

A new tool has been developed to help users of an information system for radiation oncology to analyze data and use metrics to help make more informed decisions. Varian Medical Systems (Palo Alto CA, USA), a developer of cancer treatment technology and informatics software for managing comprehensive cancer clinics, will... Read more

Industry News

view channel

Global Partnership Provides Treatment Planning Support for Modulated Arc Radiotherapy

Varian Medical Systems (Palo Alto, CA, USA) Eclipse treatment planning software can now be used to plan modulated arc radiotherapy (mARC) treatments at sites using Siemens Healthcare (Erlangen, Germany) medical linear accelerators. Varian Medical Systems and Siemens Healthcare presented their range of solutions that... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.